Kukje Pharma Co., Ltd. (KRX:002720)
South Korea
· Delayed Price · Currency is KRW 4,780.00
+30.00 (0.63%)
Apr 29, 2026, 3:30 PM KST
Kukje Pharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 175,496 | 156,463 | 135,373 | 126,583 | 119,746 | Upgrade
|
| Other Revenue | -0 | -0 | -0 | -0 | -0 | Upgrade
|
| Revenue | 175,496 | 156,463 | 135,373 | 126,583 | 119,746 | Upgrade
|
| Revenue Growth (YoY) | 12.16% | 15.58% | 6.94% | 5.71% | -8.17% | Upgrade
|
| Cost of Revenue | 81,851 | 73,968 | 68,148 | 63,329 | 65,275 | Upgrade
|
| Gross Profit | 93,645 | 82,495 | 67,225 | 63,254 | 54,470 | Upgrade
|
| Selling, General & Admin | 83,587 | 72,895 | 66,699 | 56,119 | 53,538 | Upgrade
|
| Research & Development | 3,663 | 1,811 | 2,646 | 1,967 | 2,772 | Upgrade
|
| Amortization of Goodwill & Intangibles | 11.35 | 19.91 | 199.15 | 233.84 | 227.46 | Upgrade
|
| Operating Expenses | 87,460 | 75,793 | 69,214 | 57,982 | 56,146 | Upgrade
|
| Operating Income | 6,185 | 6,702 | -1,989 | 5,273 | -1,676 | Upgrade
|
| Interest Expense | -908.41 | -1,206 | -1,440 | -1,000 | -696.43 | Upgrade
|
| Interest & Investment Income | 480.66 | 428.67 | 394.02 | 230.88 | 114.3 | Upgrade
|
| Earnings From Equity Investments | - | - | - | 23.21 | -72.91 | Upgrade
|
| Currency Exchange Gain (Loss) | 34.39 | 303.91 | 163.51 | 450.12 | 589.96 | Upgrade
|
| Other Non Operating Income (Expenses) | 843.44 | 492.72 | -2,254 | 270.73 | 627.72 | Upgrade
|
| EBT Excluding Unusual Items | 6,635 | 6,721 | -5,126 | 5,247 | -1,113 | Upgrade
|
| Gain (Loss) on Sale of Investments | 9.38 | 0.59 | 22.11 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 15.5 | 114.27 | 290.39 | 13.93 | 31.51 | Upgrade
|
| Asset Writedown | -216.38 | -226.64 | -1,867 | -515.82 | -28.5 | Upgrade
|
| Pretax Income | 6,443 | 6,609 | -6,681 | 4,745 | -1,110 | Upgrade
|
| Income Tax Expense | 738.54 | 1,403 | 1,734 | 1,202 | 445.53 | Upgrade
|
| Earnings From Continuing Operations | 5,705 | 5,206 | -8,415 | 3,543 | -1,556 | Upgrade
|
| Minority Interest in Earnings | -7.25 | -0.9 | -0.3 | 14.56 | -3.34 | Upgrade
|
| Net Income | 5,698 | 5,205 | -8,415 | 3,557 | -1,559 | Upgrade
|
| Net Income to Common | 5,698 | 5,205 | -8,415 | 3,557 | -1,559 | Upgrade
|
| Net Income Growth | 9.46% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 20 | 20 | 20 | 20 | 20 | Upgrade
|
| Shares Outstanding (Diluted) | 20 | 20 | 20 | 20 | 20 | Upgrade
|
| Shares Change (YoY) | 0.08% | 0.39% | -0.03% | -0.03% | -0.03% | Upgrade
|
| EPS (Basic) | 280.00 | 256.00 | -415.49 | 175.58 | -76.93 | Upgrade
|
| EPS (Diluted) | 280.00 | 256.00 | -415.49 | 175.58 | -77.14 | Upgrade
|
| EPS Growth | 9.38% | - | - | - | - | Upgrade
|
| Free Cash Flow | 2,216 | 1,029 | 2,529 | 5,245 | 7,705 | Upgrade
|
| Free Cash Flow Per Share | 108.92 | 50.60 | 124.88 | 258.88 | 380.18 | Upgrade
|
| Gross Margin | 53.36% | 52.73% | 49.66% | 49.97% | 45.49% | Upgrade
|
| Operating Margin | 3.52% | 4.28% | -1.47% | 4.17% | -1.40% | Upgrade
|
| Profit Margin | 3.25% | 3.33% | -6.22% | 2.81% | -1.30% | Upgrade
|
| Free Cash Flow Margin | 1.26% | 0.66% | 1.87% | 4.14% | 6.43% | Upgrade
|
| EBITDA | 9,411 | 9,904 | 2,215 | 9,760 | 2,743 | Upgrade
|
| EBITDA Margin | 5.36% | 6.33% | 1.64% | 7.71% | 2.29% | Upgrade
|
| D&A For EBITDA | 3,226 | 3,203 | 4,204 | 4,488 | 4,419 | Upgrade
|
| EBIT | 6,185 | 6,702 | -1,989 | 5,273 | -1,676 | Upgrade
|
| EBIT Margin | 3.52% | 4.28% | -1.47% | 4.17% | -1.40% | Upgrade
|
| Effective Tax Rate | 11.46% | 21.23% | - | 25.34% | - | Upgrade
|
| Advertising Expenses | 3,324 | 3,692 | 6,015 | 7,504 | 7,250 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.